Skip to content

Korro Bio, Inc.

KRRO· NasdaqCore metricsCIK 1703647

Pharmaceutical preparations551 peers

Last sale
Nov 12, 2026 · -0.80%
Market cap
$196.07M
13.73M shares
Filings
836
$0.00
Q3 2026+181.5% FY25 yoy
-$17.55M
Q3 2026N/M FY25 yoy
-$18.46M
Q3 2026N/M FY25 yoy
-$46.09M
Q3 2026derivedN/M FY25 yoy
-$0.98
Q3 2026N/M FY25 yoy
$40.22M
Q3 2026−60.8% FY25 yoy
$196.07M
—
151.8×
2.2×
-32.58%
—

Twelve months to Sep 30, 2026 · derived

Price

$14.2956.09%$18.25past year
Nov 12, 2026 · IEX last sale
Figure
Range
IEX last saleClose of recordAs traded

Last sale prices: Data provided for free by IEX. By accessing or using IEX Historical Data, you agree to the IEX Historical Data Terms of Use.

Financials

Revenue

$6.39MFY 2025
$36.98M0FY 2019FY 2020FY 2021FY 2022FY 2023FY 2024FY 2025
PeriodEndedValueKindSource trail
FY 20252025-12-31$6,392,000reported
FY 20242024-12-31$2,271,000reported
FY 20232023-12-31$0reported
FY 20222022-12-31$0reported
FY 20212021-12-31$14,068,000reported
FY 20202020-12-31$36,984,000reported
FY 20192019-12-31$28,947,000reported

Pharmaceutical preparations

Korro Bio, Inc. is the 185th largest of the 552 covered companies the SEC files under this code, by revenue. SIC 2834

Peers are the covered companies filed under the same SIC code, then under codes that share its first three digits or its first two, nearest in revenue first. Figures are each company’s latest fiscal year as filed; market cap is at its latest price.

Korro Bio, Inc. · CIK 1703647 · Engraved from SEC EDGAR